Handelsavisen
prelaunch
Companies Healthcare ORTB.ST
OR
ORTB.ST Nasdaq Stockholm Advanced Medical Equipment & Technology

Ortoma AB

kr7,43
Open in Charts → Attach watcher ⌖
SEK
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
0,00 %
Op margin
-127,8 %
ROE
-3,3 %
Net margin
-126,1 %
Debt / equity
0,00
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

Ortoma AB is a Swedish company that develops and commercializes medical devices, primarily focused on orthopedic and sports medicine solutions, generating revenue through product sales and licensing agreements.

Business. Ortoma AB (ORTB.ST) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in Sweden and is listed on the Nasdaq Stockholm exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
ActivityHealthcare Equipment
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-3,3 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ORTB.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ORTB.ST. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Ortoma AB (ORTB.ST) is a healthcare company operating in the Advanced Medical Equipment & Technology industry, primarily engaged in the sale of healthcare equipment. The firm is headquartered in Sweden and is listed on the Nasdaq Stockholm exchange. Specific details regarding its operating segments and geographic revenue mix are not available.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryAdvanced Medical Equipment & Technology
    ActivityHealthcare Equipment
    AI synthesis
    GENERATED

    Ortoma AB operates with a capital structure that is entirely equity-funded, as evidenced by a debt-to-equity ratio of 0.0. The company's liquidity position is characterized by a current ratio of 3.12, indicating a strong short-term liquidity buffer relative to its current liabilities. However, the company's operating cash flow is negative at -6,364,870 SEK, and free cash flow is also negative at -6,540,980 SEK, suggesting that the company is not generating sufficient cash from operations to sustain its activities without external financing.

    Profitability metrics are negative across the board. The company reported a net loss of -5,600,160 SEK, with a return on equity of -3.33% and a return on assets of -3.04%. These figures are significantly below the industry median for profitability metrics, indicating that Ortoma is underperforming relative to its peers in the Advanced Medical Equipment & Technology industry.

    Geographically and segment-wise, the company's revenue is not disclosed by region or product line in the available data. However, the absence of segmental breakdowns suggests that Ortoma may be concentrated in a single geographic market or product offering, which could expose it to higher concentration risk. The company's growth trajectory is also unclear, as the available data does not provide a multi-year revenue history or forward-looking guidance.

    The company's risk profile is marked by low liquidity and dilution risk, with no immediate filing-based flags detected. However, the negative operating and free cash flows suggest a potential need for future financing, which could lead to dilution if the company issues additional shares. The absence of long-term debt is a positive factor, but the company's reliance on equity financing could increase its cost of capital over time.

    Recent events and filings do not provide specific details on Ortoma's strategic initiatives or operational changes. Analyst estimates suggest that the company is expected to continue reporting losses, with a mean EPS estimate of -1.02 SEK and a mean EBIT estimate of -39,000,000 SEK. These estimates indicate that the company is not expected to achieve profitability in the near term, and its revenue is projected to remain below analyst expectations.

    Key takeaways
    • Ortoma AB is currently operating at a net loss with negative cash flows from operations and free cash flow.
    • The company is entirely equity-funded, with no long-term debt, but its liquidity position is strong due to a high current ratio.
    • Profitability metrics are significantly below industry medians, indicating underperformance relative to peers.
    • The company's geographic and segmental exposure is not disclosed, suggesting potential concentration risk.
    • Analysts expect continued losses, with no indication of near-term profitability or revenue growth.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 4

    Ortoma AB maintains zero long-term debt, providing a debt-to-equity ratio of 0.0 that exceeds the cohort median of 0.11.

    The company's cash conversion metric of 1.14 ranks above the cohort median of 0.82, indicating superior operational efficiency.

    Revenue growth trajectory shows an increase from 38.1 million SEK in FY2024 to 64.6 million SEK in FY2026.

    Dilution and liquidity risks are assessed as low, suggesting stable capital structure and market access conditions.

    BEAR CASE · 4

    Operating margin of -1.28 is significantly below the cohort median of -0.14, indicating severe profitability challenges relative to peers.

    The company carries a high credit risk flag, signaling potential difficulties in meeting financial obligations or securing financing.

    Net margin of -1.26 falls well below the cohort median of -0.16, reflecting persistent inability to generate net income.

    Capex to revenue ratio of -0.90 places the company in the bottom quartile, suggesting inefficient capital deployment.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-02-26
    Q4 2025 · Quarter highlights

    Revenue kr 4.7M, −72,7% YoY; Operating income −103,1% YoY.

    Revenuekr 4.7M−72,7 % YoY
    Operating income-kr 22.5M−103,1 % YoY
    Net income-kr 22.2M−111,0 % YoY
    Free cash flow-kr 19.3M−125,4 % YoY
    EPS
    Operating cash flowkr 6.0M+127,4 % YoY
    Financials
    Income statement
    Revenuekr 4.7M
    Gross profit-kr 10.0M
    Operating income-kr 22.5M
    Net income-kr 22.2M
    Margins
    Gross margin-211.8%
    Operating margin-479.1%
    Net margin-471.5%
    FCF margin-410.6%
    Balance sheet
    Total assetskr 161.3M
    Total liabilitieskr 18.6M
    Total equitykr 142.7M
    Cash & equivalents
    Long-term debtkr 0.00
    Cash flow
    Operating cash flowkr 6.0M
    CapEx-kr 3.1M
    Free cash flow-kr 19.3M
    SBC
    P&L flow · revenue → net income
    Revenue kr 4.7MOperating costs kr 27.2MNet income kr 22.2M
    Highlights
    • Revenue kr 4.7M, −72,7% YoY
    • Operating income −103,1% YoY
    • Net income −111,0% YoY
    • Free cash flow −125,4% YoY
    • Net margin -471.5%

    Valuation TTM

    Market price
    kr7,43
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    kr167.9M
    Net cash
    Current ratio
    3.1
    Debt / equity
    0.0
    ROA
    -3.0%
    ROE
    -3.3%
    Cash conversion
    114.0%
    CapEx / revenue
    -90.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -1,02
    Predicted surprise
    0,00
    Beat probability
    45 %
    Analysts
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-16 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-1,02
    Revenueno estimateno estimate73,0M SEK
    Operating incomeno estimateno estimate-39,0M SEK
    Full-year consensus mean (period as reported by source) · consensus in SEK. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Operating income · consensus-39,0M SEK
    EPS surprise
    +50,5 %
    reported vs consensus · beat
    Revenue surprise
    −11,5 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-127,8 %Below median
    Net Margin-126,1 %Below median
    ROE-3,3 %Below median
    Capex / Rev-90,0 %Bottom quartile
    D/E0,00Above median
    Cash Conv1,14Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • Ortoma AB Market data — financials · 2026-05-28
    • Ortoma AB Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ORTB.STCanonical
    Nasdaq Stockholm · SEK

    Intel & risk

    PredictorBeat prob45 %Surprise0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-02-26 07:13 UTCEARNINGSQuarterly results — Q4 2025 Revenue SEK 4.7M · Net SEK -22.2M
    2026-02-26 07:13 UTCEARNINGSAnnual results — FY 2026 Revenue SEK 64.6M · Net SEK -19.2M
    2025-11-05 08:53 UTCEARNINGSQuarterly results — Q3 2025 Revenue SEK 2.4M · Net SEK -14.6M
    2025-07-30 07:03 UTCEARNINGSQuarterly results — Q2 2025 Revenue SEK 18.8M · Net SEK 1.3M
    2025-05-14 07:37 UTCEARNINGSQuarterly results — Q1 2025 Revenue SEK 38.7M · Net SEK 16.3M
    2025-02-27 07:24 UTCEARNINGSQuarterly results — Q4 2024 Revenue SEK 17.3M · Net SEK -10.5M
    2025-02-27 07:24 UTCEARNINGSAnnual results — FY 2025 Revenue SEK 49.1M · Net SEK -11.6M
    2024-10-31 07:32 UTCEARNINGSQuarterly results — Q3 2024 Revenue SEK 9.9M · Net SEK -0.9M
    2024-07-18 07:07 UTCEARNINGSQuarterly results — Q2 2024 Revenue SEK 17.5M · Net SEK 5.4M
    2024-05-23 07:30 UTCEARNINGSQuarterly results — Q1 2024 Revenue SEK 4.4M · Net SEK -5.6M
    2024-02-20 08:13 UTCEARNINGSAnnual results — FY 2024 Revenue SEK 38.1M · Net SEK -21.9M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage